We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

35 hedge funds and large institutions have $16.3M invested in Xilio Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

0% more funds holding

Funds holding: 35 → 35 (0)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0.93% less ownership

Funds ownership: 4.04% → 3.11% (-0.93%)

34% less capital invested

Capital invested by funds: $24.7M → $16.3M (-$8.37M)

Holders
35
Holders Change
–
Holders Change %
0%
% of All Funds
0.47%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
6
Increased
8
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$209K
2
Morgan Stanley
Morgan Stanley
New York
+$139K
3
APP
Avantax Planning Partners
Iowa
+$135K
4
Two Sigma Investments
Two Sigma Investments
New York
+$65.8K
5
Millennium Management
Millennium Management
New York
+$45.9K

Top Sellers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
-$2.87M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$459K
3
Fidelity International
Fidelity International
Bermuda
-$209K
4
Renaissance Technologies
Renaissance Technologies
New York
-$107K
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$79.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Mariner
26
Mariner
Kansas
$18.1K – – –
SPIA
27
Steward Partners Investment Advisory
New York
$14.5K – – –
DF
28
Dunhill Financial
United Kingdom
$7.44K +$9.22K +734 New
PFG
29
Pinnacle Financial Group
Illinois
$7.24K – – –
IAMOG
30
Investors Asset Management of Georgia
Georgia
$7.24K +$8.97K +714 New
FDCDDQ
31
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.39K – – –
KFI
32
Key Financial Inc
Pennsylvania
$601 – – –
PWMG
33
Private Wealth Management Group
New Jersey
$225 – – –
Bank of America
34
Bank of America
North Carolina
$210 +$25 +2 +11%
JP Morgan Chase
35
JP Morgan Chase
New York
$45 -$13 -1 -20%
RSCM
36
Rock Springs Capital Management
Maryland
– -$2.87M -214,519 Closed
Fidelity International
37
Fidelity International
Bermuda
– -$209K -15,622 Closed
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
– -$46.9K -3,507 Closed
Citadel Advisors
39
Citadel Advisors
Florida
– -$38.5K -2,880 Closed
XT
40
XTX Topco
Cayman Islands
– -$12.3K -919 Closed
TRCT
41
Tower Research Capital (TRC)
New York
– -$2.61K -195 Closed
1
2

XLO Hedge Fund Activity: Q1 2025 in Review

35 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2025, worth a combined $16.3M — down 34% from $24.7M a quarter earlier.

Fund positioning in XLO was balanced in Q1 2025: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 7 trimmed.

The largest buyer was Vanguard Group, adding an estimated $209K. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $2.87M sold.

  • 35 institutional investors held Xilio Therapeutics (XLO) as of Q1 2025, unchanged from Q4 2024.
  • Funds reported $16.3M of Xilio Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
  • 6 funds opened new Xilio Therapeutics positions in Q1 2025 and 6 closed out, a net change of 0 holders.
  • The largest Xilio Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $209K added.
  • The largest Xilio Therapeutics seller in Q1 2025 was Rock Springs Capital Management, an estimated $2.87M sold.

Based on aggregated 13F filings for Q1 2025.